RANKL biology: bone metabolism, the immune system, and beyond.

Ono T, Hayashi M, Sasaki F, Nakashima T. · 2020

Read RANKL biology: bone metabolism, the immune system, and beyond. by Ono T, Hayashi M, Sasaki F, Nakashima T. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7006158.txt.

Introduction

Ono and co-authors review RANKL, a signal that links bone, immunity, and much more. Their review appeared in Inflammation and Regeneration. RANKL tells precursor cells to become osteoclasts, the cells that eat bone. Its partners, the receptor RANK and the decoy osteoprotegerin, form a system without which bone diseases such as osteopetrosis follow.

RANKL was first found as a T cell product that activates dendritic cells. It also builds lymph nodes and shapes immune cell development, a dual role that founded the field of osteoimmunology. The signal reaches further still: mammary glands, hair follicles, body temperature, muscle metabolism, and tumour growth. In skin, sunlight triggers it in surface cells, expanding regulatory T cells that calm inflammation. The review gathers current knowledge of the trio across all these processes. Few single signals, the authors show, touch so many systems.

Catalog record

CREATOROno T, Hayashi M, Sasaki F, Nakashima T.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7006158

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

RANKL biology: bone metabolism, the immune system, and beyond By Takehito Ono, Mikihito Hayashi, Fumiyuki Sasaki, Tomoki Nakashima Published in: Inflammation and Regeneration DOI: 10.1186/s41232-019-0111-3 ABSTRACT Abstract Receptor activator of NF-κB (RANK) ligand (RANKL) induces the differentiation of monocyte/macrophage–lineage cells into the bone–resorbing cells called osteoclasts. Because abnormalities in RANKL, its signaling receptor RANK, or decoy receptor osteoprotegerin (OPG) lead to bone diseases such as osteopetrosis, the RANKL/RANK/OPG system is essential for bone resorption. RANKL was first discovered as a T cell-derived activator of dendritic cells (DCs) and has many functions in the immune system, including organogenesis, cellular development. The essentiality of RANKL in the bone and the immune systems lies at the root of the field of “osteoimmunology.” Furthermore, this cytokine functions beyond the domains of bone metabolism and the immune system, e.g., mammary gland and hair follicle formation, body temperature regulation, muscle metabolism, and tumor development. In this review, we will summarize the current understanding of the functions of the RANKL/RANK/OPG system in biological processes. Keywords: RANKL, RANK, OPG, Bone, Immune system, Osteoimmunology, Organ development, Tumor BACKGROUND The original identification of the RANKL/RANK/OPG triad took place in the late 1990s [1]. Receptor activator of NF-κB (RANK) ligand (RANKL) and its receptor RANK were discovered in the field of immunology [2]. In the first report, a novel cytokine of the tumor necrosis factor (TNF) family was shown to be highly expressed in T cells in response to T cell receptor (TCR) signaling, and was termed tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE) [3]. At almost the same time, another group cloned the receptor gene using a human dendritic cell (DC) cDNA library and its ligand, using a cDNA library of a murine thymoma cell line. In this study, the pair of the ligand and its receptor was designated as RANKL and RANK. The authors demonstrated that RANK expression is induced on differentiated CD4+ T cells and CD40 ligand (CD40L)-stimulated mature DCs, and that RANKL stimulation enhances T cell proliferation and T cell-DC interaction [4]. Both RANKL and RANK were shown to be crucial for the development of osteoclasts and the lymph nodes (LNs) [5, 6]. Osteoprotegerin (OPG) and osteoclastogenesis inhibitory factor (OCIF) were discovered as the result of the search for osteoclastogenesis–inhibiting factors, and later turned out to be the same molecule [7, 8]. Soon after the discovery, binding partners for OPG, OPG ligand (OPGL), and osteoclast differentiation factor (ODF) were identified [9, 10]. It was later shown that both OPGL and ODF were identical to RANKL. The ODF receptor (ODFR) was shown to be a signaling receptor for ODF and identical to RANK [11]. The triad of the ligand/signaling receptor/decoy receptor is now called RANKL/RANK/OPG. The studies above together with later studies revealed the pivotal roles of RANKL, RANK, and OPG in both bone metabolism and the immune system. In addition, these molecules have been shown to be involved in diverse physiological and pathological contexts. THE STRUCTURES OF RANKL/RANK/OPG RANKL, RANK, and OPG belong to the TNF and its receptor superfamilies. As a TNF superfamily molecule, RANKL forms a homotrimer and binds to its receptors. RANK and OPG act as a monomer and homodimer, respectively. The crystal structures of the RANK–RANKL and OPG–RANKL complex have been resolved at 2.7 Å resolution [12]. RANKL The human RANKL gene (gene symbol: TNFSF11) is located on chromosome 13 (13q14.11) and encodes a glycoprotein with 317 amino acids. Human and mouse RANKL share 85% identity in their amino acid sequences. RANKL belongs to the TNF cytokine superfamily. RANKL is a type II transmembrane protein with an extracellular domain at the carboxy–terminus [1, 2]. This ectodomain is cleaved by enzymes such as matrix metalloproteinases and released to the extracellular environment as soluble RANKL. Both membrane-bound and soluble RANKL bind to RANK, but the former seems to be more functionally significant than the latter at present (see below) [13–17]. RANK The human RANK gene (gene symbol: TNFRSF11A) is located on chromosome 18 (18q21.33) and encodes a receptor with 616 amino acids. Human and mouse RANK share 66% identity in their amino acid sequences. RANK belongs to the TNF receptor superfamily. The extracellular and intracellular domains of RANK contain four cysteine-rich pseudorepeats at the amino–terminus and three TRAF-binding domains at the carboxy–terminus, respectively [1, 2]. RANK is mainly expressed in osteoclast precursors, mature osteoclasts, and immune cells such as DCs, macrophages, and microglia. A recent study demonstrated that the osteoclast releases RANK-expressing extracellular vesicles, which interact with the RANKL on osteoblasts. The interaction results in the promotion of bone formation by RANK–RANKL reverse signaling [18]. OPG The human OPG gene (gene symbol: TNFRSF11B) is located on chromosome 8 (8q24.12) and encodes a receptor with 401 amino acids. Human and mouse OPG share 85% identity in their amino acid sequences. OPG also belongs to the TNF receptor superfamily. The domains of OPG contain four cysteine-rich pseudorepeats at the amino-terminus and two death domains at the carboxy-terminus, respectively [1, 2]. OPG is exported into the extracellular space as a soluble decoy receptor without any transmembrane structure. RANKL IN BONE METABOLISM Bone undergoes a cycle of osteoclastic bone resorption and osteoblastic bone formation, i.e., the process of bone remodeling. The osteoclast is a large multinucleated cell that degrades the bone matrix with acid and catalytic enzymes. Osteoclasts are derived from monocyte/macrophage lineage cells by stimulation with the essential cytokine for osteoclastogenesis, RANKL [2, 19]. Bone development In bone tissue, RANKL is expressed by several types of cells including osteoblasts, osteocytes and immune cells. Among these cells, RANKL expression is higher in osteoblasts and osteocytes. In neonatal or young mice in their growth period, hypertrophic chondrocytes in the growth plate and osteoblasts are the major sources of RANKL. In older mice, on the other hand, osteocytes contribute more to RANKL expression (Fig. 1a) [20–22]. RANKL binds to its corresponding receptor RANK, thereby inducing subsequent osteoclastogenic signals. [Figure: RANKL in bone metabolism. a The RANKL–RANK interaction in bone development and remodeling. Hypertrophic chondrocytes and osteoblasts function as the source of RANKL during growth. After the growth period, osteocytes are the major source of RANKL. RANKL induces the differentiation of osteoclasts, which resorb bone matrix. b RANKL–RANK interaction in bone and joint diseases related to immobility and aging. The bone loss induced by unloading is induced by osteocyte RANKL. B cell RANKL is reported to partially contribute to the bone loss in postmenopausal osteoporosis, as well. c In the lesion that occur in rheumatoid arthritis, synovial fibroblasts stimulated with pro-inflammatory cytokines, including IL-17, express RANKL and enhance osteoclastogenesis. In periodontitis, RANKL is mainly provided by PDL cells and osteoblasts. (see also Table 2). The IL-17 in these processes is produced by TH17 cells stimulated by IL-6. TH17 cells (exFoxp3 TH17 cells, in particular) express RANKL as well. RANKL receptor activator of NF-κB ligand, RANK receptor activator of NF-κB, TH17 cell T helper 17 cell, PDL periodontal ligament] Hereditary bone diseases Because of its essentiality in osteoclastogenesis, dysregulation of RANKL signaling results in excessive or impaired bone resorption, and certain therapeutic interventions in such dysregulated signaling have been shown to be effective in the treatment of bone diseases [1]. Mutations in genes encoding RANKL, RANK, and OPG lead to hereditary bone diseases

Read the complete text